3-Methoxy-4,5-methylendioxyamphetamine

From Wikipedia, the free encyclopedia

MMDA
Chemical name	3-methoxy-4,5-Methylenedioxyamphetamine or 1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-amine
Chemical formula	C11H15NO3
Molecular mass	209.2417 g/mol
Melting point	133-134 °C (hydrochloride)
CAS numbers	13674-05-0
SMILES	CC(N)Cc1cc2OCOc2c(c1)OC

MMDA, 3-MeO-4,5-MDA, 3-methoxy-4,5-methylenedioxy-phenylisopropylamine, or 3-methoxy-4,5-methylendioxyamphetamine has stimulant, psychedelic, entheogenic, and entactogenic effects in man.

Contents 1 Chemistry 2 Dosage 3 Effects 4 Psychotherapuetic actions 5 Pharmacology 6 Legality 7 See also 8 External links

[edit] Chemistry

MMDA, 1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-amine, is a biologically active phenethylamine and amphetamine derivative. Its analogues include MDA, lophophine and MDMA, and it bears resemblance to the psychopharmacologically active essential oils elemicin and myristicin found in nutmeg.

[edit] Dosage

The effective dose of MMDA is 120-150 mg. Most typically taken by mouth via pressed tablets or intranasaly via powder.

[edit] Effects

The first symptoms appear within 30-60 minutes following oral administration. Moderate mydriasis, dizziness, sensations of heat or cold, and trembling are occasionally reported as side effects. Psychologically, the most frequently reported effects are accentuation of feelings (anxiety, euphoria, loneliness, loving warmth), the visualization of images (with eyes closed), a state of drowsiness and muscular relaxation, and an overestimation of elapsed time.

The imagery is generally realistic, and often related to everyday perception of people, landscapes. or objects. The effects of MMDA usually reach a peak after the first hour following the initial symptoms, and begin to wane during the second hour, and usually completely disappear by the end of the fifth hour.

[edit] Psychotherapuetic actions

In his 1973 book, "The Healing Journey," Claudio Naranjo explored the psychotherapeutic potential of MMDA. Like MDA, he found that MMDA facilitates communication and suggested it has potential applications in psychotherapy. Worldwide as of 2005, MMDA has not been approved for any human applications.

[edit] Pharmacology

The mechanism that produces the psychedelic activity of MMDA is unknown. There are, as of the present time, no reported studies on the human pharmacokinetics or metabolism of MMDA.

[edit] Legality

MMDA is classified as a Schedule 1 substance in the United States, and is similarly controlled in other parts of the world. Internationally, MMDA is a Schedule I drug under the Convention on Psychotropic Substances[1].

[edit] See also

• MDA
• MDMA
• PiHKAL

[edit] External links

• PIHKAL entry for MMDA
• MMDA: A New Psychotomimetic Agent
• Animal Pharmacology and Human Psychopharmacology of MMDA
• A Pharmacological Comparison of MMDA and LSD In The Dog

• Links to external chemical sources.

Empathogen-entactogens - edit
5-MeO-DALT | α-ET | Bk-MBDB | Bk-MDEA | DMMDA-2 | IAP | Bk-MDMA | MBDB | MDEA | MDA | MDMA | MMDA

Hallucinogenic phenethylamines edit
2C-B, 2C-B-FLY, 2C-C, 2C-D, 2C-E, 2C-G, 2C-I, 2C-N, 2C-O, 2C-O-4, 2C-P, 2C-T, 2C-T-2, 2C-T-4, 2C-T-7, 2C-T-8, 2C-T-9, 2C-T-21, 2C-TFM, 3C-E, 3C-P, Br-DFLY, DESOXY, DMMDA-2, DOB, DOC, DOET, DOI, DOM, DON, Escaline, Isoproscaline, Lophophine, MDA, MMDA, Macromerine, Mescaline, Proscaline, TMA